1	Title: Impacts of vaccination and Severe Acute Respiratory Syndrome Coronavirus 2 variants
2	Alpha and Delta on Coronavirus Disease 2019 transmission dynamics in four metropolitan areas
3	of the United States
4	Running Title: Impacts of COVID-19 vaccination and SARS-CoV-2 variants
5	One-Sentence Summary: Using a compartmental model parameterized to reproduce available
6	reports of new Coronavirus Disease 2019 (COVID-19) cases, we quantified the impacts of
7	vaccination and Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2) variants
8	Alpha (lineage B.1.1.7) and Delta (lineage B.1.617.2) on regional epidemics in the metropolitan
9	statistical areas (MSAs) surrounding Dallas, Houston, New York City, and Phoenix.
10 11	Authors: Abhishek <u>Mallela¹</u> , Ye <u>Chen¹</u> , Yen Ting <u>Lin</u> , Ely F. <u>Miller</u> , Jacob <u>Neumann</u> , Zhili <u>He</u> , Kathryn E. <u>Nelson</u> , Richard G. <u>Posner</u> , William S. <u>Hlavacek</u> *
12	¹ These authors contributed equally.
13	Corresponding author. Email: <u>wish@lanl.gov</u>
14	Address for correspondence: William S. Hlavacek, Theoretical Biology and Biophysics
15	Group, Theoretical Division, Los Alamos National Laboratory, Los Alamos, NM 87545,
16	USA.
17	Affiliations: Los Alamos National Laboratory, Los Alamos, New Mexico, USA (W.S.
18	Hlavacek, Y.T. Lin, A. Mallela); Northern Arizona University, Flagstaff, Arizona, USA (Y.
19	Chen, Z. He, E.F. Miller, K.E. Nelson, J. Neumann, R.G. Posner).

21 ABSTRACT

To characterize Coronavirus Disease 2019 (COVID-19) transmission dynamics in each of 22 the metropolitan statistical areas (MSAs) surrounding Dallas, Houston, New York City, and 23 Phoenix in 2020 and 2021, we extended a previously reported compartmental model accounting 24 for effects of multiple distinct periods of non-pharmaceutical interventions by adding 25 consideration of vaccination and Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-26 27 CoV-2) variants Alpha (lineage B.1.1.7) and Delta (lineage B.1.617.2). For each MSA, we found region-specific parameterizations of the model using daily reports of new COVID-19 cases 28 available from January 21, 2020 to October 31, 2021. In the process, we obtained estimates of 29 30 the relative infectiousness of Alpha and Delta as well as their takeoff times in each MSA (the times at which sustained transmission began). The estimated infectiousness of Alpha ranged 31 from 1.1x to 1.6x that of viral strains circulating in 2020 and early 2021. The estimated relative 32 33 infectiousness of Delta was higher in all cases, ranging from 1.6x to 2.2x. The estimated Alpha takeoff times ranged from February 16 (for New York City, which was evidently impacted much 34 earlier than the other regions) to April 2, 2021. The estimated Delta takeoff times were more 35 tightly clustered, ranging from June 15 to June 24, 2021. Estimated takeoff times are consistent 36 with genomic surveillance data. 37

38

Keywords: Coronavirus Disease 2019 (COVID-19), Severe Acute Respiratory Syndrome
Coronavirus 2 (SARS-CoV-2), vaccination, SARS-CoV-2 variant Alpha (lineage B.1.1.7),
SARS-CoV-2 variant Delta (lineage B.1.617.2), mathematical model, Bayesian inference

43 INTRODUCTION

44	In 2020, Coronavirus Disease 2019 (COVID-19) transmission dynamics were
45	significantly influenced by non-pharmaceutical interventions [1–7]. In 2021, other factors arose
46	with significant impacts on disease transmission, namely, vaccination [8-9] and emergence of
47	Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2) variants [10-11].
48	Mass vaccination in the United States (US) began on December 14, 2020 [12], with
49	demonstrable reduction of disease burden within vaccinated populations [13]. As the vaccination
50	campaign progressed into March 2021, there was widespread reduction in disease incidence [14]
51	and relaxation of state-mandated non-pharmaceutical interventions [15].
52	In early 2021, SARS-CoV-2 variant Alpha (lineage B.1.1.7) spread across the US and
53	became the dominant circulating strain [16]. By the end of July 2021, the Delta variant (lineage
54	B.1.617.2) had supplanted Alpha [17], concomitant with increases in new COVID-19 case
55	detection [14]. Both Alpha and Delta have been estimated to be more transmissible than strains
56	circulating earlier [18-23], and it was determined that vaccinated persons infected with Alpha
57	and Delta were capable of transmitting disease [24, 25].
58	In earlier work, with the aid of a compartmental model, we quantified the impact of non-
59	pharmaceutical interventions on COVID-19 transmission dynamics [5–7]. We found that the
60	multiple surges in disease incidence seen in 2020 [14] could be explained by changes in
61	protective disease-avoiding behaviors, which we will refer to collectively as social distancing.
62	Here, to quantify the impacts of vaccination and SARS-CoV-2 variants Alpha and Delta on
63	COVID-19 transmission dynamics, we extended the model of Lin et al. [5] by adding
64	consideration of vaccination and variants with increased transmissibility. We then found region-

65	specific parameterizations of the model using vaccination and surveillance case data available for
66	the MSAs surrounding Dallas, Houston, New York City, and Phoenix.

67 METHODS

68 Data

Daily reports of new confirmed COVID-19 cases were obtained from the GitHub
repository maintained by The New York Times newspaper [26]. Daily reports of newly
completed vaccinations were obtained from the Covid Act Now database [27]. County-level
surveillance and vaccination data were aggregated to obtain daily case and vaccination counts for
the MSAs surrounding Dallas, Houston, New York City, and Phoenix. In the case of a missing
daily report, we imputed the missing information as described in the Appendix.

75 Compartmental Model for Disease Transmission Dynamics

We used the compartmental model illustrated in Figure 1 (and Appendix Figure 1) to
analyze data available for each MSA of interest. The model consists of ordinary differential
equations (ODEs) describing the dynamics of 40 populations (state variables) (Appendix
Equations 1–38). The state variables are each defined in Appendix Table 1. Model parameters
are defined in Tables 1–3. Key features of the model are described below, and a full description
of the model is provided in the Appendix.

We extended the model of Lin et al. [5] by including 15 new populations and 28 new transitions. The new compartments and transitions, which are highlighted in Figure 1, capture vaccination among susceptible persons, recovered persons and infected non-quarantined persons without symptoms at a time-varying *per capita* rate $\mu(t)$. The value of $\mu(t)$ changes daily for

consistency with MSA-specific daily reports of completed vaccinations (Appendix Equation 37) 86 from the COVID Act Now database. The model also captures immune responses to vaccination 87 yielding varying degrees of protection and consequences of breakthrough infection of vaccinated 88 persons. Vaccine protection against transmissible infection was taken to be variant-dependent. 89 We introduced a dimensionless step function, denoted $Y_{\theta}(t)$ (Appendix Equation 38), 90 which multiplies the disease-transmission rate constant β to account for *m* variants. In this study, 91 m = 2 (see Appendix Equations 1–4, 18–22, and 24). Thus, in the new model, the quantity 92 $Y_{\theta}(t)\beta$ (vs. β alone) characterizes disease transmissibility at time t. The step function $Y_{\theta}(t)$ was 93 initially assigned a value of $y_0 = 1$, and the value of $Y_{\theta}(t)$ was allowed to increase at times t =94 θ_1 and $t = \theta_2$ (Appendix Equation 38). The disease transmission rate constant of the Alpha 95 variant was considered by introducing a step increase from $y_0\beta \equiv 1\beta$ to $y_1\beta$ (with $y_1 > 1$) at 96 time $t = \theta_1$ (the Alpha takeoff time). Similarly, the disease transmission rate constant of the 97 Delta variant was considered by introducing a step increase from $y_1\beta$ to $y_2\beta$ (with $y_2 > y_1$) at 98 time $t = \theta_2 > \theta_1$ (the Delta takeoff time). We will refer to y_1 and y_2 as the Alpha and Delta 99 transmissibility factors, respectively. 100

As in the original model of Lin et al. [5], the extended model accounts for a series of n +1 distinct social-distancing periods (an initial period and n additional periods). Social-distancing periods are characterized by two step functions: $P_{\tau}(t)$ and $\Lambda_{\tau}(t)$. The values of these functions change coordinately at a set of times $\tau = (\sigma, \tau_1, ..., \tau_n)$ (Appendix Equations 35 and 36), where σ is the start time of the initial social-distancing period and τ_i is the start time of the *i*th socialdistancing period after the initial social-distancing period. The values of $P_{\tau}(t)$ and $\Lambda_{\tau}(t)$ are zero before time $t = \sigma$. The value of $P_{\tau}(t)$ defines the steady-state setpoint fraction of the susceptible

108 population practicing social distancing at time t, and the value of $\Lambda_{\tau}(t)$ defines a time scale for 109 establishment of the steady state. The value of $\Lambda_{\tau}(t)$ is an eigenvalue equal to a sum of social-110 distancing rate constants (5). The non-zero values of $P_{\tau}(t)$ and $\Lambda_{\tau}(t)$ are denoted p_0, \dots, p_n and 111 $\lambda_0, \dots, \lambda_n$. We assume that vaccinated persons do not practice social-distancing. Recall that we 112 use the term "social-distancing" to refer to behaviors adopted to protect against infection. These 113 behaviors are assumed to reduce the risk of infection by a factor m_h .

114 **Parameters**

As indicated in Tables 1 and 2, we used MSA-specific case reporting data available up to 115 October 31, 2021 to infer MSA-specific values for parameters characterizing the start time of the 116 local epidemic (t_0) , local disease transmissibility of ancestral viral strains (β) , local social-117 118 distancing dynamics (σ , λ_0 , p_0 , τ_i , λ_i and p_i , for i = 1, ..., n), local emergence of variants (θ_1 , y_1, θ_2, y_2), the local rate of new case detection (f_D) , and noise in local case detection and 119 120 reporting (r). Values for other parameters were fixed (Table 3); inferences are conditioned on these fixed parameter estimates. There are 18 fixed parameters taken to be applicable for all 121 122 MSAs. The total regional population S_0 , which is taken to be fixed, was set on the basis of census data. The real-time *per capita* vaccination rate $\mu(t)$, a piecewise linear function, was set 123 for consistency with the current empirical per capita rate of vaccination [27]. We adopted the 124 fixed parameter estimates of Lin et al. [5]. New fixed parameter estimates made in this study for 125 m_h , f_0 , f_1 , f_2 , and k_V are explained in the Appendix. The m_h parameter characterizes vaccine 126 protection against severe disease, the f_0 , f_1 , and f_2 parameters account for differential vaccine 127 effectiveness against the three viral strains considered in this study (ancestral, Alpha, and Delta), 128 129 and the k_V parameter characterizes the waiting time between vaccination and the acquisition of

vaccine-induced immunity. Our model does not account for gradual loss of immunity over time. 130 We let $\tilde{\mu}(t) = \mu_i$ for times t throughout the *i*th day after January 21, 2020 (Appendix Equation 131 37), where μ_i is the fraction of the local population reported to complete vaccination over the 1-d 132 surveillance period [27]. We then defined $\mu(t)$ as the piecewise linear interpolant to $\tilde{\mu}(t)$. In 133 134 summary, for a given inference, the number of adjustable parameters was 2m + 3n + 5, where m is the number of variants under consideration (m = 2 in this study) and n is the number of 135 distinct social-distancing periods being considered beyond an initial social-distancing period. 136 The setting for *n* was determined through a model-selection procedure described in the 137 Appendix. 138

139 Auxiliary Measurement Model

140 We assumed that state variables of the compartmental model (Figure 1, Appendix Table 1) are related to the expected number of new cases reported on a given calendar date through an 141 142 auxiliary measurement model (Appendix Equations 39 and 40). The measurement model has one parameter: f_D , the region-specific fraction of new symptomatic infections detected. Thus, $f_D \in$ 143 [0, 1]. As a simplification, we considered f_D to be time-invariant. This simplification means that 144 we assumed, for example, that case detection was neither limited nor strongly influenced by 145 testing capacity, which varied over time. This assumption is reasonable if, for example, case 146 detection is mainly determined by presentation for testing and, moreover, the motivations and 147 societal factors that influence presentation remained roughly constant over the period of interest. 148 One can also interpret f_D as the time-averaged case detection rate. The measurement-model 149 150 parameter f_D was inferred jointly with the adjustable model parameters and the likelihood parameter r (see below). 151

152 Statistical Model for Noise in Case Detection and Reporting

We assumed that noise in new case detection and reporting on the *i*th day after January 153 21, 2020 is captured by a negative binomial distribution NB (r, q_i) centered on $I(t_i, t_{i+1})$, the 154 expected number of new cases detected over the *i*th day after January 21, 2020 as given by the 155 compartmental model and the auxiliary measurement model (Appendix Equations 1-40). These 156 and other assumptions led to the likelihood function used in inference (Appendix Equations 41– 157 43). We determined the probability parameter q_i in NB (r, q_i) using Appendix Equation 43; the 158 159 dispersion parameter r was taken to be a time-invariant adjustable parameter applicable for all days of case reporting. The likelihood parameter r was inferred jointly with the adjustable model 160 parameters and the adjustable measurement-model parameter f_D . 161

162 Computational Methods

We determined the intervals of the step functions $Y_{\theta}(t)$, $P_{\tau}(t)$, and $\Lambda_{\tau}(t)$ (i.e., θ and τ) 163 using a model-selection procedure described in the Appendix. Simulations and Bayesian 164 165 inferences were performed as previously described [5–7] and in the Appendix. Files needed to reproduce inferences using the software package PyBioNetFit [28] are available online 166 (https://github.com/lanl/PyBNF/tree/master/examples/Vax and Variants). The files include case 167 168 data, vaccination data, and diagnostic plots related to Bayesian inference using Markov chain Monte Carlo (MCMC) sampling. Summary diagnostics characterizing the sampling for each 169 170 MSA are given in Table 4. The results of Table 4 indicate that sampling was acceptable.

171 **RESULTS**

In earlier work, we demonstrated that new COVID-19 case detection over various periods
in 2020 can be faithfully reproduced for 280 (out of the 384) metropolitan statistical areas

(MSAs) in the US and all 50 states by region-specific parameterizations of a compartmental 174 model that accounts for time-varying non-pharmaceutical interventions [5–7]. However, in 2021, 175 the model lost its ability to capture disease transmission dynamics, presumably because of the 176 impacts of vaccination and the emergence of more transmissible SARS-CoV-2 variants, namely, 177 Alpha and Delta. To remedy this problem, we accounted for these factors in an extension of the 178 179 model of Lin et al. [5] (Figure 1). Details about the model extension are provided in the Appendix. We used the new model to analyze data available for four MSAs (Figures 2-5). 180 As illustrated in Figures 2A, 3A, 4A, and 5A for the Dallas, Houston, New York City, 181 and Phoenix MSAs respectively, the new model is able to explain surveillance case data over the 182 period starting on January 21, 2020 and ending on October 31, 2021. The surveillance case 183 data-daily reports of newly detected COVID-19 cases-for each of the 4 MSAs of interest 184 largely lie within the 95% credible interval of the posterior predictive distribution for new case 185 detection, which indicates that each regional model has explanatory power for the period of 186 interest. 187 Each regional model (parameterized to reproduce MSA-specific case reports) provides 188 insight into the impacts of social-distancing behaviors and the emergence of the Alpha and Delta 189 190 variants; compare panel A and the corresponding panel B in Figures 2–5. For example, as can be seen in Figure 4A, the New York City MSA experienced four notable surges in disease incidence 191 over the period of interest. Figure 4B suggests that the first surge ended because of adoption of 192 193 social-distancing behaviors, the second surge occurred because of relaxation of social-distancing behaviors, the third surge was caused by Alpha, and the fourth surge was caused by Delta. 194 195 Interestingly, in other MSAs, Alpha had relatively little impact on disease incidence (compare 196 Figures 4A and 4B to Figures 2A and 2B, 3A and 3B, and 5A and 5B). This difference is partly

attributable to the later arrival of Alpha in the Dallas, Houston, and Phoenix MSAs in
combination with the progress of mass vaccination, which is tracked locally in panel C of
Figures 2–5.

On the basis of our region-specific parameterizations, we estimated the immune and susceptible fractions of each MSA population, as well as the fractions that achieved immunity through infection and/or vaccination (see panel C in Figures 2–5). Each of these panels shows the time evolution of five different populations in an MSA. In each MSA, only a minority of the population remained susceptible to infection (with Delta) on October 31, 2021, with a sizable fraction of the susceptible population being protected to a degree against severe disease by having completed vaccination.

Our inferences provide quantitative insights into the increased transmissibility of Alpha 207 and Delta $(y_1 \text{ and } y_2)$ and their takeoff times $(\theta_1 \text{ and } \theta_2)$ in each of the 4 MSAs of interest. 208 Figure 6 shows the marginal posteriors of y_1 , y_2 , θ_1 , and θ_2 , which were found on the basis of 209 surveillance data for each MSA (daily case counts) reported between January 21, 2020 and 210 October 31, 2021. Maximum a posteriori (MAP) estimates and 95% credible intervals for θ_1 and 211 θ_2 for each MSA are also shown in Figure 6. The MAP estimates for y_1 range from 1.1 (for the 212 Dallas MSA) to 1.6 (for the Phoenix MSA). The MAP estimates for y_2 range from 1.6 (for the 213 Dallas MSA) to 2.2 (for the New York City MSA). The MAP estimates for θ_1 range from 214 215 February 16, 2021 (for the New York City MSA) to April 2, 2021 (for the Phoenix MSA). The New York City MSA was impacted much earlier than the other MSAs by Alpha. The MAP 216 estimates for θ_2 range from June 15, 2021 (for the New York City MSA) to June 24, 2021 (for 217 the Dallas MSA). The estimated takeoff times are consistent with regional genomic surveillance 218 219 data [30], which are summarized by the shaded regions of panel A in Figures 2–5.

220 DISCUSSION

We extended a model for COVID-19 transmission dynamics that already incorporated 221 222 time-varying changes in non-pharmaceutical interventions [5] to include the effects of vaccination and new variants. This model together with its region-specific parameterizations 223 based on case data available through October 31, 2021 provide quantitative insights into the 224 relative infectiousness of SARS-CoV-2 variants Alpha (lineage B.1.1.7) and Delta (lineage 225 226 B.1.617.2). The increased transmissibility of Alpha and Delta in comparison to ancestral strains is characterized by the marginal posteriors for the transmissibility factors y_1 and y_2 shown in 227 Figure 6 (panels A, C, E, and G). The maximum a posteriori (MAP) estimates of the 228 transmissibility factors were similar across the four metropolitan statistical areas (MSAs) of 229 interest (centered on Dallas, Houston, New York City, and Phoenix). The averages of our y_1 and 230 y_2 MAP estimates indicate that Alpha was 1.3x more infectious than ancestral strains, whereas 231 Delta was 2.0x more infectious (corresponding to Delta being 54% more infectious than Alpha). 232 233 These estimates are consistent with estimates provided in other studies [18–23]. This information 234 combined with our earlier estimates of MSA-specific basic reproduction numbers [7] indicate 235 that Delta is among one of the most infectious viruses known. We obtain an R_0 estimate of 16 for 236 the New York City MSA.

We also obtained estimates of precisely when sustained transmission of Alpha and Delta began in each of the four MSAs. The takeoff times are characterized by the marginal posteriors for θ_1 and θ_2 shown in Figure 6 (panels B, D, F, and H). The takeoff times are similar across the MSAs except that the New York City MSA was evidently impacted much earlier by Alpha: circa February 16, 2021 vs. circa late March to early April 2021 for the other MSAs. The estimated takeoff times are consistent with the observed prevalence of Alpha and Delta sequences detected

243	in regional genomic surveillance [30], as can be seen by comparing the two shaded regions in
244	panel A of Figures 2–5 against the changes in transmissibility $Y_{\theta}(t)$ depicted in the
245	corresponding panel B of Figures 2–5. It should be noted that the case data shown in Figures 2–5
246	are from the MSAs of interest (through aggregation of county-level data), whereas the genomic
247	surveillance data are from larger regions.
248	Our study has notable limitations, starting with the obvious uncertainties related to model
249	assumptions and fixed parameter estimates, which are discussed in some detail in the Appendix.
250	For example, our model neglects gradual loss of sterilizing immunity over time and assumes a
251	constant rate of case detection. Moreover, we caution that the inference jobs performed in this
252	study were challenging because of the relatively high-dimensional parameter spaces involved (in
253	comparison to typical inferences involving an ODE model-constrained likelihood function).
254	Diagnostics indicate good sampling (Table 4,
255	https://github.com/lanl/PyBNF/tree/master/examples/Vax_and_Variants), but we cannot be
256	entirely certain that the samples obtained fully characterize the parameter posteriors of interest.
257	Another concern is that the model incorporates redundant disease-incidence surge mechanisms.
258	In the model, an increase in viral infectiousness caused by the emergence of a new variant can be
259	mimicked, to some extent, by a relaxation of social distancing, and vice versa. For the MSAs
260	considered here, inferred social-distancing levels were low at the time of Alpha and Delta
261	emergence, so the inferred transmissibility factors probably reflect, at least mostly, changes in
262	intrinsic viral infectiousness.

263 ACKNOWLEDGMENTS

264	W.S.H., Y.T.L., and A.M. were supported by the LDRD program at Los Alamos National
265	Laboratory (project 20220268ER). Y.C., Z.H., E.F.M., J.N., K.E.N., and R.G.P. were supported
266	by a grant from the National Institute of General Medical Sciences of the National Institutes of
267	Health (grant R01GM111510). A.M. was supported by the 2020 Mathematical Sciences
268	Graduate Internship program, which is sponsored by the Division of Mathematical Sciences of
269	the National Science Foundation, and the Center for Nonlinear Studies at Los Alamos National
270	Laboratory. Computational resources used in this study included Northern Arizona University's
271	Monsoon computer cluster, which is funded by Arizona's Technology and Research Initiative
272	Fund, and the FARM computer cluster at the University of California, Davis. Y.C. thanks Song
273	Chen (University of Wisconsin, La Crosse, Wisconsin, USA) for technical assistance.
274	REFERENCES
275	[1] Courtemanche C, Garuccio J, Le A, Pinkston J, Yelowitz A. Strong social distancing
276	measures in the United States reduced the COVID-19 growth rate. Health Aff
277	(Millwood). 2020;39:1237-46. https://doi.org/10.1377/hlthaff.2020.00608
278	[2] Hsiang S, Allen D, Annan-Phan S, Bell K, Bolliger I, Chong T, et al. The effect of large-
279	scale anti-contagion policies on the COVID-19 pandemic. Nature. 2020;584:262-7.
280	https://doi.org/10.1038/s41586-020-2404-8
281	[3] Matrajt L, Leung T. Evaluating the effectiveness of social distancing interventions to
282	delay or flatten the epidemic curve of coronavirus disease. Emerg Infect Dis.
283	2020;26:1740-8. https://doi.org/10.3201/eid2608.201093
284	[4] Bo Y, Guo C, Lin C, Zeng Y, Li HB, et al. Effectiveness of non-pharmaceutical
285	interventions on COVID-19 transmission in 190 countries from 23 January to 13 April
286	2020. Int J Inf Dis. 2021;102:247-53. https://doi.org/10.1016/j.ijid.2020.10.066

287	[5]	Lin YT,	Neumann	J, Mill	er EF,	Posner	RG,	Mallela A	, Safta	C, Ray	уJ,	Thakur	G,
-----	-----	---------	---------	---------	--------	--------	-----	-----------	---------	--------	-----	--------	----

- 288 Chinthavali S, Hlavacek WS. Daily forecasting of regional epidemics of Coronavirus
- 289 Disease with Bayesian uncertainty quantification, United States. Emerg Infect Dis.
- 290 2021;27:767–78. <u>https://doi.org/10.3201/eid2703.203364</u>
- [6] Mallela A, Neumann J, Miller EF, Chen Y, Posner RG, Lin YT, Hlavacek WS. Bayesian
- inference of state-level COVID-19 basic reproduction numbers across the United States,
 Viruses. 2022;14:157. https://doi.org/10.3390/v14010157
- [7] Mallela A, Lin YT, Hlavacek WS. Differential contagiousness of respiratory disease
- across the United States, medRxiv. 2022. <u>https://doi.org/10.1101/2022.09.15.22279948</u>
- [8] Oliver SE, Gargano JW, Marin M, Wallace M, Curran KG, Chamberland M, et al. The

297 Advisory Committee on Immunization Practices' interim recommendation for use of

- 298 Pfizer-BioNTech COVID-19 vaccine—United States, December 2020. MMWR Morb
- 299 Mortal Wkly Rep. 2020;69:1922–4. <u>https://doi.org/10.15585/mmwr.mm6950e2</u>
- 300 [9] Oliver SE, Gargano JW, Marin M, Wallace M, Curran KG, Chamberland M, et al. The
- 301 Advisory Committee on Immunization Practices' interim recommendation for use of
- 302 Moderna COVID-19 vaccine—United States, December 2020. MMWR Morb Mortal
- 303 Wkly Rep. 2021;69:1653–6. <u>https://doi.org/10.15585/mmwr.mm695152e1</u>
- 304 [10] Galloway SE, Paul P, MacCannell DR, Johansson MA, Brooks JT, MacNeil A, et
- al. Emergence of SARS-CoV-2 B.1.1.7 lineage—United States, December 29, 2020–
- 306 January 12, 2021. MMWR Morb Mortal Wkly Rep. 2021 / 70(3);95–99.
- **307** <u>http://dx.doi.org/10.15585/mmwr.mm7003e2</u>
- Herlihy R, Bamberg W, Burakoff A, Alden N, Severson R, Bush E, et al. Rapid
 increase in circulation of the SARS-CoV-2 B.1.617.2 (Delta) variant—Mesa County,

- Colorado, April–June 2021. MMWR Morb Mortal Wkly Rep. 2021;70:1084–7.
- 311 <u>https://doi.org/10.15585/mmwr.mm7032e2</u>
- 312 [12] Department of Health and Human Services. COVID-19 Vaccine Milestones [cited
- 313 2022 Dec 21] <u>https://www.hhs.gov/coronavirus/covid-19-</u>
- 314 vaccines/distribution/index.html
- 315 [13] Daniel W, Nivet M, Warner J, Podolsky DK. Early evidence of the effect of
- SARS-CoV-2 vaccine at one medical center. N Engl J Med. 2021;384:1962–3.
- 317 <u>https://doi.org/10.1056/NEJMc2102153</u>
- 318 [14] Centers for Disease Control and Prevention. COVID data tracker. 2021 [cited
- 319 2021 Oct 6] <u>https://covid.cdc.gov/covid-data-tracker/#datatracker-home</u>
- 320 [15] Coronavirus Resource Center, Johns Hopkins University. Impact of opening and
- 321 closing decisions by state: a look at how social distancing measures may have influenced
- trends in COVID-19 cases and deaths. 2021 [cited 2021 Oct 6]
- 323 <u>https://coronavirus.jhu.edu/data/state-timeline</u>
- 324 [16] Washington NL, Gangavarapu K, Zeller M, Bolze A, Cirulli ET, Schiabor Barrett
- 325 KM, et al. Emergence and rapid transmission of SARS-CoV-2 B.1.1.7 in the United
- 326 States. Cell. 2021;184:2587–94. <u>https://doi.org/10.1016/j.cell.2021.03.052</u>
- 327 [17] Centers for Disease Control and Prevention. Covid data tracker, variant
- proportions. 2021 [cited 2021 Oct 6] <u>https://covid.cdc.gov/covid-data-tracker/#variant-</u>
 proportions
- 330 [18] Volz E, Mishra S, Chand M, Barrett JC, Johnson R, Geidelberg L, et al. Assessing
- transmissibility of SARS-CoV-2 lineage B.1.1.7 in England. Nature. 2021;593:266–9.
- 332 https://doi.org/10.1038/s41586-021-03470-x

- 333 [19] Davies NG, Abbott S, Barnard RC, Jarvis CI, Kucharski AJ, Munday JD, et al.
- Estimated transmissibility and impact of SARS-CoV-2 lineage B.1.1.7 in England.
- 335 Science. 2021;372:eabg3055. <u>https://doi.org/10.1126/science.abg3055</u>
- 336 [20] Ito K, Piantham C, Nishiura H. Predicted dominance of variant Delta of SARS-
- 337 CoV-2 before Tokyo Olympic Games, Japan, July 2021. Euro Surveill.
- 338 2021;26:2100570. <u>https://doi.org/10.2807/1560-7917.ES.2021.26.27.2100570</u>
- 339 [21] Arav Y, Fattal E, Klausner Z. Increased transmissibility of emerging SARS-CoV-
- 2 variants is driven either by viral load or probability of infection rather than
- environmental stability. Mathematics. 2022, 10(19), 3422.
- 342 https://doi.org/10.3390/math10193422
- 343 [22] Public Health England. SARS-CoV-2 variants of concern and variants under
- investigation in England. Technical briefing 15, June 11, 2021. [cited 2021 Aug 24]
- 345 <u>https://assets.publishing.service.gov.uk/government/uploads/system/uploads/attachment</u>
- 346 data/file/993879/Variants of Concern VOC Technical Briefing 15.pdf
- 347 [23] Cascella M, Rajnik M, Aleem A, Dulebohn SC, Di Napoli R. Features,
- evaluation, and treatment of coronavirus (COVID-19). July 30, 2021 update. Treasure
- 349 Island (FL): StatPearls Publishing; 2022.
- 350 <u>https://www.ncbi.nlm.nih.gov/books/NBK554776/</u>
- 351 [24] Lopez Bernal J, Andrews N, Gower C, Gallagher E, Simmons R, Thelwall S, et
- al. Effectiveness of Covid-19 Vaccines against the B.1.617.2 (Delta) variant. N Engl J
- 353 Med. 2021;385:585–94. <u>https://doi.org/10.1056/NEJMoa2108891</u>
- 354 [25] Rovida F, Cassaniti I, Paolucci S, Percivalle E, Sarasini A, Piralla A, et al. SARS-
- 355 CoV-2 vaccine breakthrough infections with the alpha variant are asymptomatic or

- mildly symptomatic among health care workers. Nat Commun. 2021;12:6032.
- 357 <u>https://doi.org/10.1038/s41467-021-26154-6</u>
- 358 [26] The New York Times. Coronavirus (Covid-19) data in the United States. 2021
- 359 [cited 2021 Aug 24] <u>https://github.com/nytimes/covid-19-data</u>
- Covid Act Now. US COVID risk and vaccine tracker. 2021 [cited 2021 Sep 29]
- 361 <u>https://covidactnow.org/</u>
- 362 [28] Neumann J, Lin YT, Mallela A, Miller EF, Colvin J, Duprat AT, Chen Y,
- 363 Hlavacek WS, Posner RG. Implementation of a practical Markov chain Monte Carlo
- sampling algorithm in PyBioNetFit. Bioinformatics. 2022;38:1770–2.
- 365 https://doi.org/10.1093/bioinformatics/btac004
- 366 [29] Vats D, Knudson C. Revisiting the Gelman-Rubin Diagnostic. Statist. Sci.
- 367 2021;36:518–529. <u>https://doi.org/10.1214/20-STS812</u>
- 368 [30] Centers for Disease Control and Prevention. SARS-CoV-2 Variant Proportions.
- 369 2023 [cited 2023 Mar 8] <u>https://data.cdc.gov/Laboratory-Surveillance/SARS-CoV-2-</u>
- 370 <u>Variant-Proportions/jr58-6ysp</u>

Table 1. Model parameter values inferred for the Dallas, Houston, New York City, and Phoenix

373 Metropolitan Statistical Areas (MSAs) on October 31, 2021

Parameter	MAP estimate*	MAP estimate*	MAP estimate* for	MAP estimate*
	for Dallas	for Houston	New York City	for Phoenix
	(Units)	(Units)	(Units)	(Units)
t_0	12.0 (d)	11.7 (d)	8.6 (d)	15.0 (d)
β	$0.29 (d^{-1})$	$0.29 (d^{-1})$	$0.37 (d^{-1})$	$0.28 (d^{-1})$
σ	57 (d)	58 (d)	60 (d)	56 (d)
p_0	0.31	0.32	0.48	0.32
λ_{0}	$6.8 (d^{-1})$	$6.8 (d^{-1})$	$10.0 (d^{-1})$	$8.5 (d^{-1})$
$ au_1$	62 (d)	61 (d)	64 (d)	40 (d)
p_1	0.26	0.26	0.41	0.20
λ_1	$2.2 (d^{-1})$	$2.4 (d^{-1})$	$3.1 (d^{-1})$	$1.5 (d^{-1})$
$ au_2$	46 (d)	52 (d)	29 (d)	51 (d)
p_2	0.34	0.32	0.42	0.36
λ_2	$2.0 (d^{-1})$	$2.8 (d^{-1})$	$0.34 (d^{-1})$	$3.1 (d^{-1})$
$ au_3$	83 (d)	99 (d)	76 (d)	79 (d)
p_3	0.19	0.18	0.30	0.19
λ_3	$2.4 (d^{-1})$	$2.5 (d^{-1})$	$8.3 (d^{-1})$	$1.6 (d^{-1})$
$ au_4$	131 (d)	-	-	213 (d)
p_4	0.10	-	-	0.19
λ_4	$1.6 (d^{-1})$	-	-	$2.0 (d^{-1})$

$ heta_1$	427 (d)	434 (d)	392 (d)	437 (d)
y_1	1.1	1.2	1.3	1.6
θ_2	92 (d)	83 (d)	120 (d)	80 (d)
y_2	1.6	1.8	2.2	2.2
f_D	0.37	0.32	0.39	0.53
r	3.2	2.8	9.4	3.4

374	*Maximum a posteriori (MAP) estimates are region-specific and inference-time-dependent.
375	Here, inference was based on MSA-specific confirmed coronavirus disease case count data
376	available in the GitHub repository maintained by The New York Times newspaper [26] for
377	January 21, 2020 to October 31, 2021. Time $t = 0$ corresponds to midnight on January 21, 2020.
378	Inferences were conditioned on the compartmental model of Appendix Equations 1-38,
379	consideration of two viral variants (Alpha and Delta, $m = 2$), and $n + 1$ distinct social-
380	distancing periods in total ($n = 4$ for Dallas and Phoenix; $n = 3$ for New York City and
381	Houston), the fixed parameter estimates of Table 3, and the initial condition I_0 and S_0 at time $t =$
382	t_0 given in Table 3. The choice of two variants and the setting for <i>n</i> were chosen through a
383	model-selection procedure described in the Appendix. With $m = 2$ and $n = 3$, there are 18
384	adjustable model parameters: t_0 , β , θ_1 , y_1 , θ_2 , y_2 , σ , p_0 , λ_0 , τ_1 , p_1 , λ_1 , τ_2 , p_2 , λ_2 , τ_3 , p_3 , and λ_3 .
385	With $m = 2$ and $n = 4$, there are 21 adjustable model parameters: t_0 , β , θ_1 , y_1 , θ_2 , y_2 , σ , p_0 , λ_0 ,
386	$\tau_1, p_1, \lambda_1, \tau_2, p_2, \lambda_2, \tau_3, p_3, \lambda_3, \tau_4, p_4$, and λ_4 . These parameters were jointly inferred together
387	with f_D , the parameter of the measurement model (i.e., the fraction of new cases detected and
388	reported) (Appendix Equation 40), and r , the dispersion parameter of the statistical model for
389	noise in case detection and reporting (i.e., the adjustable parameter of the negative binomial

- 390 likelihood function) (Appendix Equations 41–43). We assumed a uniform proper prior, as
- 391 described in the Appendix.

392

Parameter	Description
t_0	Start of local disease transmission
β	Rate constant for disease transmission
σ	Start of first social-distancing period
p_0	Social-distancing setpoint for the period $t \in [\sigma, \tau_1)$
λ_{0}	Social-distancing eigenvalue paired with p_0
$ au_1$	Start of second social-distancing period
p_1	Social-distancing setpoint for the period $t \in [\tau_1, \tau_2)$
λ_1	Social-distancing eigenvalue paired with p_1
$ au_2$	Start of third social-distancing period
p_2	Social-distancing setpoint for the period $t \in [\tau_2, \tau_3)$
λ_2	Social-distancing eigenvalue paired with p_2
$ au_3$	Start of fourth social-distancing period
p_3	Social-distancing setpoint for the period $t \in [\tau_3, \tau_4)$
λ_3	Social-distancing eigenvalue paired with p_3
$ au_4$	Start of fifth social-distancing period
p_4	Social-distancing setpoint for the period $t \in [\tau_4, \infty)$
λ_4	Social-distancing eigenvalue paired with p_4
$ heta_1$	Alpha takeoff time
y_1	Increased infectiousness of Alpha (relative to

Table 2. Descriptions of MSA-specific adjustable model parameters.

ancestral strains)

	$ heta_2$	Delta takeoff time
	y_2	Increased infectiousness of Delta (relative to ancestral
		strains)
	f_D	Fraction of cases detected and reported
	r	Dispersion parameter of $NB(r, q_i)^*$
395	*The probability	y parameter of NB(r, q_i) is constrained, i.e., the value of q_i , which is reporting
396	time-dependent	, is given by Appendix Equation 43.
397		
398		
399		
400		
401		
402		
403		
404		
405		
406		
407		
408		
409		
410		
411		
412		

Parameter	Estimate ¹	Description	Source
	(Units)		
I ₀	1	Number of infectious persons at time $t = t_0$	[5]
S ₀	19,216,182 ²	Total population	[5]
$\mu(t)$	Empirical	Daily per capita rate of vaccination	[27]
	time-series ³		
	(d^{-1})		
m_b	0.1	Reduction in risk of infection because of	[5]
		social distancing	
m_h	0.04	Reduction in risk of severe disease (once	This study ⁴
		symptomatic) because of vaccination	
f_A	0.44	Fraction of all cases that are asymptomatic	[5]
f_H	0.054	Fraction of symptomatic cases that are severe	[5]
		(in the absence of vaccination)	
f_R	0.79	Fraction of persons with severe disease who	[5]
		recover	
$1 - f_0$	0.1	Fraction of vaccinated persons who fail to	This study ⁴
		develop an immune response that protects	
		against productive infection by ancestral	
		strains or variants	
$f_0 - f_1$	0.09	Fraction of vaccinated persons who develop	This study ⁴
		an immune response that protects against	

413 **Table 3.** Fixed parameter estimates for each region-specific compartmental model

		productive infection by ancestral strains (but	
		not the Alpha or Delta variant)	
$f_1 - f_2$	0.12	Fraction of vaccinated persons who develop	This study ⁴
		an immune response that protects against	
		productive infection by ancestral strains and	
		the Alpha variant (but not the Delta variant)	
f_2	0.69	Fraction of vaccinated persons who develop	This study ⁴
		an immune response that protects against	
		productive infection by ancestral strains and	
		the Alpha and Delta variants	
$ ho_E$	1.1	Relative infectiousness of persons without	[5]
		symptoms in the incubation period of	
		infection	
$ ho_A$	0.9	Relative infectiousness of persons without	[5]
		symptoms in the immune-clearance phase of	
		infection	
k_L	$0.94 (d^{-1})$	Rate constant for progression through each	[5]
		stage of the incubation period of infection ⁵	
k_Q	$0.0038 (d^{-1})$	Rate constant for quarantine of infected, non-	[5]
		vaccinated persons	
j _Q	$0.4 (d^{-1})$	Rate constant for self-isolation of	[5]
		symptomatic, non-vaccinated persons	

$$c_A$$
0.26 (d^{-1})Rate constant for completion of the immune[5]clearance phase of infection for persons
without symptomsclearance phase of infection for persons[5] c_I 0.12 (d^{-1})Rate constant for completion of the immune[5]clearance phase of infection or progression to
severe disease for non-vaccinated persons
with symptoms[5] c_H 0.17 (d^{-1})Rate constant for recovery or progression to
death for non-vaccinated persons with severe
disease[5] k_V 0.3 (d^{-1})Rate constant for progression through eachThis study4

¹Fixed parameter estimates are based on information external to the surveillance data used to 414 415 infer the adjustable parameter values of Table 1. Estimates are applicable to all metropolitan statistical areas (MSAs) of interest except for S_0 and the vaccination function $\mu(t)$, which are 416 region-specific. Recall that $\mu(t)$ is updated daily for consistency with vaccination data. 417 ²The total population S_0 is MSA-specific. Here, S_0 is given for the New York City MSA. The 418 initial susceptible population is taken to be the total population. We used $S_0 = 7,573,136$, 419 7,066,141, and 4,873,019 for the Dallas, Houston, and Phoenix MSAs, respectively. 420 ³The function $\mu(t)$ is determined by region-specific vaccination data [27]. 421 422 ⁴See the Appendix for more information about estimates of fixed parameter values made in this study. 423

- ⁵As in the study of Lin et al. [5], the incubation period is divided into 5 stages (Figure 1), each of
- 425 equal duration on average.
- ⁶The immune response to vaccination is divided into 6 stages (Figure 1), each of equal duration
- 427 on average. The choice of 6 stages is justified in the Appendix and Appendix Figure 2.

- 429 **Table 4.** Multivariate potential scale reduction factors (PSRFs) and multivariate effective sample
- 430 sizes (ESSs) corresponding to the stable Gelman-Rubin statistic for Markov chains generated
- 431 using PyBioNetFit for the Dallas, Houston, New York City, and Phoenix Metropolitan Statistical
- 432 Areas (MSAs)

MSA	Multivariate	Multivariate
	PSRF ¹	ESS ¹
Dallas	1.0016	317.2
Houston	1.0021	239.9
New York City	1.0022	225.9
Phoenix	1.0034	146.2

433 ¹Computed using the methodology of Vats and Knudson [29].

434

435

436



438

Figure 1. Illustration of compartmental model. The independent variable of the model is time t. 439 The 40 dependent state variables of the model are populations, which are represented as boxes 440 with rounded corners. A description of each state variable is given in Appendix Table 1. The 15 441 highlighted boxes (on the blue background) represent state variables introduced to capture the 442 443 effects of vaccination and the Alpha and Delta variants. The other 25 boxes represent state variables considered in the model of Lin et al. [5]. Arrows connecting boxes represent 444 transitions. Each transition represents the movement of persons from one population to another. 445 446 The arrows highlighted in orange represent transitions introduced to capture the effects of vaccination and the Alpha and Delta variants. Other arrows represent transitions considered in 447 the model of Lin et al. [5]. Each arrow is associated with one or more parameters that 448 characterize a rate of movement; these parameters are not shown here but are shown in Appendix 449 Figure 1. A full description of the model is given in the Appendix. Briefly, new parts of the 450 model can be described as follows. Vaccination is modeled by moving susceptible persons (in 451

the S_M and S_P populations) into the V_1 population. Another consequence of vaccination is the 452 movement of recovered unvaccinated persons (in the R_U population) into the R_V population. The 453 rate of vaccination typically changes from day to day to match the empirical daily rate of 454 vaccination. Recovered and susceptible persons have the same per-capita probability of 455 vaccination. Persons in S_M are mixing (i.e., not practicing social distancing) and persons in S_P 456 are practicing social distancing (and thereby protected from infection to a degree). The series of 457 transitions involving the populations V_1, \ldots, V_6 was introduced to model the immune response to 458 vaccination (i.e., the amount of time required for vaccination to induce neutralizing antibodies). 459 With this approach, the time from vaccination to appearance of neutralizing antibodies is a 460 461 random variable characterized by an Erlang distribution. Persons in V_1, \dots, V_6 may be infected. Persons in V_6 transition to one of the following four populations: $S_{V,1}, \dots, S_{V,4}$. These populations 462 represent persons with varying degrees of immune protection. Persons in $S_{V,1}$ are not protected 463 against productive infection (i.e., an infection that can be transmitted to others) by any viral 464 strain. Persons in $S_{V,2}$ are protected against productive infection by viral strains present before 465 the emergence of Alpha but not Alpha or Delta. Persons in $S_{V,3}$ are protected against productive 466 infection by viral strains present before the emergence of Alpha and also Alpha but not Delta. 467 Persons in $S_{V,4}$ are protected against productive infection by all of the viral strains considered up 468 to October 31, 2021. Vaccinated persons who become infected move into E_V . The time spent in 469 E_V corresponds to the length of the incubation period for vaccinated persons. The mean duration 470 471 of the incubation period is taken to be the same for vaccinated and unvaccinated persons; 472 however, as a simplification, for vaccinated persons, the time spent in the incubation period is 473 taken to consist of a single stage and consequently is exponentially distributed (vs. Erlang 474 distributed for unvaccinated persons). All non-quarantined exposed persons (in populations E_V

and $E_{i,M}$ and $E_{i,P}$ for i = 1, ..., 5) are taken to be infectious. Persons exiting E_V leave the 475 incubation period and enter the immune clearance phase of infection, during which they may be 476 asymptomatic (A_V) or symptomatic with mild disease (I_V) . All non-quarantined asymptomatic 477 persons (in populations A_V , A_M , and A_P) are taken to be infectious. Persons in A_V are all assumed 478 to eventually recover (i.e., to enter R_{ν}). Persons with mild symptomatic disease may recover 479 (i.e., enter R_V) or experience severe disease, at which point they move to H_V (in hospital or 480 isolated at home). Vaccinated persons have a diminished probability of severe disease in 481 comparison to unvaccinated persons. Persons in H_V either recover (move to R_V) or die from 482 483 COVID-19 complications (move to *D*). For a person with severe disease, the probability of death is independent of vaccination status. We assume that vaccinated persons do not participate in 484 485 social distancing, quarantine, or self-isolation driven by symptom awareness.



Figure 2. Inference results obtained for the MSA surrounding Dallas using regional surveillance 489 data-daily reports of new COVID-19 cases-available for January 21, 2020 to October 31, 490 2021. A) Credible intervals of the time-dependent posterior predictive distribution for detected 491 and reported new cases are shown. The color bands from bottom to top indicate the 5%, 10%, ... 492 90%, 95% credible intervals. This colored region all together indicates the 95% credible interval 493 494 and can be expected to cover approximately 95% of the data. Empirical case reports are indicated by black symbols. A case count of 12,974 cases on December 11, 2020 is not shown in the plot. 495 Alpha prevalence is indicated with a shaded light-yellow background. Delta prevalence is 496 indicated with a shaded light-green background. B) The social-distancing stationary setpoint is 497 given by $P_{\tau}(t)$ and the variant transmissibility factor is given by $Y_{\theta}(t)$. Note that the values of 498 499 $P_{\tau}(t)$ and $Y_{\theta}(t)$ are dimensionless. Credible intervals corresponding to 1000 samples from the 500 time-dependent posterior predictive distributions are shown for $P_{\tau}(t)$ and $Y_{\theta}(t)$. The curve corresponding to $Y_{\theta}(t)$ is monotonically increasing with an initial value of 1. The curve 501 corresponding to $P_{\tau}(t)$ is decreasing from left to right after the start of social distancing. C) 502 Inferred changes in the distribution of persons amongst five selected subpopulations over the 503 course of the local COVID-19 epidemic. The five populations sum to a constant, S_0 , the total 504 population. Results shown here are based on the parameter values given in Tables 1 and 3. The 505 five populations are defined as follows: the population of susceptible unvaccinated persons (blue 506 area) is given by $S_M + S_P$, the population of susceptible vaccinated persons (green area) is given 507 by $\sum_{i=1}^{6} V_i + S_{V,1} + U_{\theta_1}(t)S_{V,2} + U_{\theta_2}(t)S_{V,3}$, the population of actively infected persons (orange 508 area) is given by $H_U + H_V + E_V + \sum_{i=1}^{5} (E_{i,M} + E_{i,P} + E_{i,Q}) + \sum_{x \in \{M,P,Q,V\}} (A_x + I_x)$, the 509 population of removed unvaccinated persons (gray area) is given by $R_U + D$, and the population 510 of removed vaccinated persons (yellow area) is given by $R_V + (1 - U_{\theta_1}(t))S_{V,2} +$ 511

512 $(1 - U_{\theta_2}(t))S_{V,3} + S_{V,4}$. Except for $U_{\theta_1}(t)$ and $U_{\theta_2}(t)$, the terms in the above definitions refer to

- state variables of the compartmental model of Figure 1 and Appendix Figure 1, which are
- defined in Appendix Table 1. $U_{\theta_1}(t)$ and $U_{\theta_2}(t)$ are unit step functions (Appendix Equation 33)
- and 34), which change value from 0 to 1 at time $t = \theta_1$ and $t = \theta_2$, respectively. Recall that θ_1
- and θ_2 are the Alpha and Delta takeoff times. The sum $\sum_i (\mu_i \times 1 \text{ d})$ (purple dots), which is the
- 517 empirical cumulative number of completed vaccinations, is shown as a function of time t.



- 520 Figure 3. Inference results obtained for the MSA surrounding Houston using regional
- 521 surveillance data—daily reports of new COVID-19 cases—available for January 21, 2020 to
- 522 October 31, 2021. It should be noted that four anomalous (negative) empirical case counts are
- not shown in the plot. A case count of 14,300 cases on September 21, 2020 is not shown in the
- 524 plot. See the caption of Figure 2 for additional information.



527	Figure 4. Inference results obtained for the MSA surrounding New York City using regional
528	surveillance data—daily reports of new COVID-19 cases—available for January 21, 2020 to
529	October 31, 2021. It should be noted that a single anomalous (negative) empirical case count is
530	not shown in the plot. A case count of 42,774 cases on January 3, 2021 is not shown in the plot.
531	See the caption of Figure 2 for additional information.
532	
533	
534	
525	
555	
536	
537	
538	
539	
540	



542	Figure 5. Inference results obtained for the MSA surrounding Phoenix using regional
543	surveillance data—daily reports of new COVID-19 cases—available for January 21, 2020 to
544	October 31, 2021. It should be noted that two anomalous (negative) empirical case counts are not
545	shown in the plot. A case count of 12,372 cases on January 3, 2021 is not shown in the plot. See
546	the caption of Figure 2 for additional information.
547	
548	
549	
550	
551	
551	
552	
553	
554	
555	
556	
557	

558

559



Figure 6. Marginal posterior distributions of transmissibility factors for Alpha in dark-green and
Delta in light-green (left panels) and takeoff times for Alpha and Delta (right panels) in four
MSAs centered on (A,B) Dallas, (C,D) Houston, (E,F) New York City, and (G,H) Phoenix.
Inferences are based on daily reports of new cases from January 21, 2020 to October 31, 2021.
For each of the right panels, the 95% credible intervals for Alpha and Delta takeoff times are
indicated in parentheses, and the MAP estimate for a given region is indicated to the left of the
credible interval.

569

570 APPENDIX

571 Imputation of Missing Daily Case Counts

By October 31, 2021, many regions in the US were not reporting new detected COVID-19 cases on a strictly daily basis. When one or more daily case counts were not available, we imputed daily case counts on the basis of a linear fit to the two nearest available cumulative case counts. This approach has the effect of evenly distributing case counts across the days for which

576 daily reports are unavailable.

577 Equations of the Compartmental Model

578 The compartmental model, which is illustrated in Figure 1 and Appendix Figure 1, 579 consists of the following 40 ordinary differential equations (ODEs):

$$\frac{dS_M}{dt} = -\beta Y_\theta(t) \left(\frac{S_M}{S_0}\right) \left(\phi_M(t,\rho) + m_b \phi_P(t,\rho)\right)$$

$$- U_\sigma(t) \Lambda_\tau(t) \left[P_\tau(t) S_M - \left(1 - P_\tau(t)\right) S_P\right] - \mu(t) S_0 \left(\frac{S_M}{\phi_V(t)}\right)$$
(1)

$$\frac{dS_P}{dt} = -m_b \beta Y_\theta(t) \left(\frac{S_P}{S_0}\right) \left(\phi_M(t,\rho) + m_b \phi_P(t,\rho)\right) + U_\sigma(t) \Lambda_\tau(t) \left[P_\tau(t)S_M - \left(1 - P_\tau(t)\right)S_P\right] - \mu(t)S_0 \left(\frac{S_P}{\phi_V(t)}\right)$$
(2)

$$\frac{dE_{1,M}}{dt} = \beta Y_{\theta}(t) \left(\frac{S_M}{S_0}\right) (\phi_M(t,\rho) + m_b \phi_P(t,\rho)) - k_L E_{1,M}$$
(3)
$$- U_{\sigma}(t) \Lambda_{\tau}(t) [P_{\tau}(t) E_{1,M} - (1 - P_{\tau}(t)) E_{1,P}]$$

$$\frac{dE_{1,P}}{dt} = m_b \beta Y_{\theta}(t) \left(\frac{S_P}{S_0}\right) (\phi_M(t,\rho) + m_b \phi_P(t,\rho)) - k_L E_{1,P}$$
(4)
+ $U_{\sigma}(t) \Lambda_{\tau}(t) [P_{\tau}(t) E_{1,M} - (1 - P_{\tau}(t)) E_{1,P}]$

$$\frac{dE_{i,M}}{dt} = k_L E_{i-1,M} - k_L E_{i,M} - k_Q E_{i,M} - U_\sigma(t) \Lambda_\tau(t) [P_\tau(t) E_{i,M} - (1 - P_\tau(t)) E_{i,P}],$$
(5)

for i = 2, 3, 4, 5

$$\frac{dE_{i,P}}{dt} = k_L E_{i-1,P} - k_L E_{i,P} - k_Q E_{i,P} + U_\sigma(t) \Lambda_\tau(t) \left[P_\tau(t) E_{i,M} - (1 - P_\tau(t)) E_{i,P} \right], \tag{6}$$

for
$$i = 2, 3, 4, 5$$

$$\frac{dE_{2,Q}}{dt} = k_Q (E_{2,M} + E_{2,P}) - k_L E_{2,Q}$$
(7)

$$\frac{dE_{i,Q}}{dt} = k_Q (E_{i,M} + E_{i,P}) + k_L E_{i-1,Q} - k_L E_{i,Q}, \text{ for } i = 3, 4, 5$$
(8)

$$\frac{dA_M}{dt} = f_A k_L E_{5,M} - k_Q A_M - U_\sigma(t) \Lambda_\tau(t) [P_\tau(t) A_M - (1 - P_\tau(t)) A_P] - c_A A_M$$
(9)

$$\frac{dA_P}{dt} = f_A k_L E_{5,P} - k_Q A_P + U_\sigma(t) \Lambda_\tau(t) [P_\tau(t) A_M - (1 - P_\tau(t)) A_P] - c_A A_P$$
(10)

$$\frac{dA_Q}{dt} = f_A k_L E_{5,Q} + k_Q (A_M + A_P) - c_A A_Q$$
(11)

$$\frac{dI_M}{dt} = (1 - f_A)k_L E_{5,M} - (k_Q + j_Q)I_M - U_\sigma(t)\Lambda_\tau(t)[P_\tau(t)I_M - (1 - P_\tau(t))I_P]$$
(12)
$$- c_I I_M$$

$$\frac{dI_P}{dt} = (1 - f_A)k_L E_{5,P} - (k_Q + j_Q)I_P + U_\sigma(t)\Lambda_\tau(t)[P_\tau(t)I_M - (1 - P_\tau(t))I_P] - c_I I_P$$
(13)

$$\frac{dI_Q}{dt} = (1 - f_A)k_L E_{5,Q} + (k_Q + j_Q)(I_M + I_P) - c_I I_Q$$
(14)

$$\frac{dH_U}{dt} = f_H c_I \left(I_M + I_P + I_Q \right) - c_H H_U \tag{15}$$

$$\frac{dD}{dt} = (1 - f_R)c_H H_U + (1 - f_R)c_H H_V$$
(16)

$$\frac{dR_U}{dt} = c_A (A_M + A_P + A_Q) + (1 - f_H) c_I (I_M + I_P + I_Q) + f_R c_H H_U - \mu(t) S_0 \left(\frac{R_U}{\phi_V(t)}\right)$$
(17)

$$\frac{dV_1}{dt} = \mu(t)S_0\left(\frac{S_M + S_P}{\phi_V(t)}\right) - k_V V_1 - \beta Y_\theta(t)\left(\frac{V_1}{S_0}\right)\left(\phi_M(t,\rho) + m_b\phi_P(t,\rho)\right)$$
(18)

$$\frac{dV_i}{dt} = k_V V_{i-1} - k_V V_i - \beta Y_{\theta}(t) \left(\frac{V_i}{S_0}\right) \left(\phi_M(t,\rho) + m_b \phi_P(t,\rho)\right),\tag{19}$$

for i = 2, 3, 4, 5, 6

$$\frac{dS_{V,1}}{dt} = (1 - f_0)k_V V_6 - \beta Y_\theta(t) \left(\frac{S_{V,1}}{S_0}\right) \left(\phi_M(t,\rho) + m_b \phi_P(t,\rho)\right)$$
(20)

$$\frac{dS_{V,2}}{dt} = (f_0 - f_1)k_V V_6 - U_{\theta_1}(t)\beta Y_{\theta}(t) \left(\frac{S_{V,2}}{S_0}\right) \left(\phi_M(t,\rho) + m_b \phi_P(t,\rho)\right)$$
(21)

$$\frac{dS_{V,3}}{dt} = (f_1 - f_2)k_V V_6 - U_{\theta_2}(t)\beta Y_{\theta}(t) \left(\frac{S_{V,3}}{S_0}\right) \left(\phi_M(t,\rho) + m_b \phi_P(t,\rho)\right)$$
(22)

$$\frac{dS_{V,4}}{dt} = f_2 k_V V_6 \tag{23}$$

$$\frac{dE_{V}}{dt} = \beta Y_{\theta}(t) \left(\frac{1}{S_{0}}\right) \left(\phi_{M}(t,\rho) + m_{b}\phi_{P}(t,\rho)\right)$$

$$\cdot \sum_{i=1}^{6} \left(V_{i} + S_{V,1} + U_{\theta_{1}}(t)S_{V,2} + U_{\theta_{2}}(t)S_{V,3}\right) - \left(\frac{k_{L}}{5}\right)E_{V}$$

$$\frac{dA_{V}}{dt} = f_{A}\left(\frac{k_{L}}{5}\right)E_{V} - c_{A}A_{V}$$
(24)
(24)
(24)
(25)

$$\frac{dI_V}{dt} = (1 - f_A) \left(\frac{k_L}{5}\right) E_V - c_I I_V \tag{26}$$

$$\frac{dH_V}{dt} = m_h f_H c_I I_V - c_H H_V \tag{27}$$

$$\frac{dR_V}{dt} = \mu(t)S_0\left(\frac{R_U}{\phi_V(t)}\right) + c_A A_V + (1 - m_h f_H)c_I I_V + f_R c_H H_V$$
(28)

- 580 In these equations, the independent variable is time t, and the state variables $(S_M, S_P,$
- 581 $E_{1,M}, \dots, E_{5,M}, E_{1,P}, \dots, E_{5,P}, E_{2,Q}, \dots, E_{5,Q}, A_M, A_P, A_Q, I_M, I_P, I_Q, H_U, D, R_U, V_1, \dots, V_6,$

 $S_{V,1}, \dots, S_{V,4}, E_V, A_V, I_V, H_V$, and R_V) represent 40 (sub)populations (Appendix Table 1), which change over time. Thus, each ODE in Equations (1)–(28) defines the time-rate of change of a population, i.e., the time-rate of change of a state variable. Note that Equations (5), (6), (8) and (19) define 4, 4, 3, and 5 ODEs of the model, respectively. The model is formulated such that S_0 , the total population, is a constant. Thus, the model does not account for birth, death for reasons other than COVID-19, immigration, or emigration.

- 588 The initial condition associated with Equations (1)–(28) is taken to be $S_M(t_0) = S_0$,
- 589 $I_M(t_0) = I_0 = 1$, and all other populations $(S_P, E_{1,M}, \dots, E_{5,M}, E_{1,P}, \dots, E_{5,P}, E_{2,Q}, \dots, E_{5,Q}, A_M)$
- 590 $A_P, A_Q, I_P, I_Q, H_U, D, R_U, V_1, \dots, V_6, S_{V,1}, \dots, S_{V,4}, E_V, A_V, I_V, H_V$, and R_V) are equal to 0. Recall

that the parameter S_0 denotes the total region-specific population size. Thus, we assume that the entire population is susceptible at the start of the local epidemic at time $t = t_0 > 0$, where time t = 0 corresponds to 0000 hours (midnight) on January 21, 2020. The parameter I_0 denotes the number of infectious symptomatic persons at the start of the regional epidemic.

In the model, the parameters β , k_L , k_Q , j_Q , c_A , c_I , c_H , and k_V are positive-valued rate constants (all with units of d⁻¹), and the parameters m_b , m_h , f_A , f_H , f_R , $f_0 \ge f_1$, $f_1 \ge f_2$, and f_2 are (dimensionless) fractions. Brief definitions of parameters are given in Tables 1 and 2.

598 In the model, the quantities $\phi_M(t,\rho)$, $\phi_P(t,\rho)$, and $\phi_V(t)$ are functions of (timedependent) state variables (as defined below), which represent the population of infectious 599 persons who are mixing freely (i.e., not practicing social distancing), the population of infectious 600 persons who are practicing social distancing (i.e., adopting disease-avoiding behaviors), and the 601 population of persons eligible for vaccination, respectively. The quantities $\phi_M(t,\rho)$ and $\phi_P(t,\rho)$ 602 are also functions of $\rho \equiv (\rho_E, \rho_A)$, where $\rho_E (\rho_A)$ is a dimensionless ratio representing the 603 infectiousness of persons in the incubation phase of infection (the infectiousness of 604 605 asymptomatic persons in the immune clearance phase of infection) relative to the infectiousness of symptomatic persons with the same social-distancing behavior. The quantity $\phi_{V}(t)$ represents 606 the population of persons eligible for vaccination. 607

$$\phi_M(t,\rho) = I_M + I_V + \rho_E (E_{2,M} + E_{3,M} + E_{4,M} + E_{5,M} + E_V) + \rho_A (A_M + A_V)$$
(29)

$$\phi_P(t,\rho) = I_P + \rho_E (E_{2,P} + E_{3,P} + E_{4,P} + E_{5,P}) + \rho_A A_P$$
(30)

$$\phi_V(t) = S_M + S_P + \sum_{i=1}^5 (E_{i,M} + E_{i,P}) + A_M + A_P + R_U$$
(31)

The state variables that appear in these equations represent time-varying populations. Recall thatstate variables are defined in Appendix Table 1.

In the model, the quantities $U_{\sigma}(t)$, $U_{\theta_1}(t)$, and $U_{\theta_2}(t)$ are unit step functions. The values of these functions change from 0 to 1 at the times indicated by the subscripts: σ , the onset time of the initial social-distancing period; θ_1 , the takeoff time of SARS-CoV-2 variant Alpha; and θ_2 , the takeoff time of SARS-CoV-2 variant Delta.

$$U_{\sigma}(t) = \begin{cases} 0 & t < \sigma \\ 1 & t \ge \sigma \end{cases}$$
(32)

$$U_{\theta_1}(t) = \begin{cases} 0 & t < \theta_1 \\ 1 & t \ge \theta_1 \end{cases}$$
(33)

$$U_{\theta_2}(t) = \begin{cases} 0 & t < \theta_2 \\ 1 & t \ge \theta_2 \end{cases}$$
(34)

As indicated in Appendix Figure 1, transitions from S_M to S_P , for example, become possible at time $t = \sigma$, transitions from $S_{V,2}$ to E_V become possible at time $t = \theta_1$, and transitions from $S_{V,3}$ to E_V become possible at time $t = \theta_2$.

617 In the model, the quantities $P_{\tau}(t)$, and $\Lambda_{\tau}(t)$ are step functions that characterize changes 618 in social distancing. The value of $P_{\tau}(t)$ determines a setpoint steady-state fraction of susceptible 619 persons who are practicing social distancing. The value of $\Lambda_{\tau}(t)$ determines a time scale for 620 approach to the setpoint steady state. Changes in the values of $P_{\tau}(t)$ and $\Lambda_{\tau}(t)$ occur 621 coordinately. These changes occur at times $t = \sigma, \tau_1, ..., \tau_n$, where *n* is the number of distinct

social-distancing periods beyond an initial social-distancing period. Initially, we took n = 7 (i.e., 8 total social-distancing stages). The value of n is decremented by 1 (at an inferred time) if $n \leftarrow$ n - 1 is determined to be admissible by a model-selection procedure, which is described below. It should be noted that $p_0, p_1, ..., p_n$ are parameters of $P_{\tau}(t)$ and that $\lambda_0, \lambda_1, ..., \lambda_n$ are parameters of $\Lambda_{\tau}(t)$. These parameters determine the non-zero values of the step functions over different periods. For example, p_1 is the value of $P_{\tau}(t)$ and λ_1 is the value of $\Lambda_{\tau}(t)$ for the period $t \in$ $[\tau_1, \tau_2)$.

$$P_{\tau}(t) = \begin{cases} p_{0} & \sigma \leq t < \tau_{1} \\ p_{1} & \tau_{1} \leq t < \tau_{2} \\ \vdots & \vdots \\ p_{n} & \tau_{n} \leq t < \infty \end{cases}$$
(35)

$$\Lambda_{\tau}(t) = \begin{cases} \lambda_0 & \sigma \le t < \tau_1 \\ \lambda_1 & \tau_1 \le t < \tau_2 \\ \vdots & \vdots \\ \lambda_n & \tau_n \le t < \infty \end{cases}$$
(36)

629 The values of $P_{\tau}(t)$ and $\Lambda_{\tau}(t)$ are 0 for $t < \sigma$.

In the model, the quantity $\mu(t)$ is a piecewise linear interpolant to a function $\tilde{\mu}(t)$ that characterizes the current rate of vaccination. The value of $\tilde{\mu}(t)$ is determined by the empirical daily rate of vaccination, and thus, can vary from day to day. Daily vaccination data were extracted from the Covid Act Now database using the Covid Act Now Data API [1]. We will use μ_i to refer to the value of $\tilde{\mu}(t)$ for $t \in [t_i, t_{i+1})$, where time t_i corresponds to midnight on the *i*th day after January 21, 2020.

$$\tilde{\mu}(t) = \mu_i \text{ for } t \in [t_i, t_{i+1}) \tag{37}$$

636 Settings for μ_i were made such that $\mu_i S_0 \times 1$ d is the number of vaccinations completed in the 637 nearest past 1-d period according to Covid Act Now data.

In the model, the quantity $Y_{\theta}(t)$ is a step function that quantifies how disease 638 transmissibility increases upon emergence of SARS-CoV-2 variants Alpha and Delta. Initially, 639 $Y_{\theta}(t) = 1$. The value of $Y_{\theta}(t)$ is increased (by an inferred factor greater than 1 at an inferred 640 time, θ_1 or θ_2) if the change is determined to be admissible by a model-selection procedure, 641 which is described below. It should be noted that y_1 and y_2 are parameters of $Y_{\theta}(t)$. These 642 643 parameters determine the values of the step function $Y_{\theta}(t)$ over different periods: y_1 is the value of $Y_{\theta}(t)$ for the period $t \in [\theta_1, \theta_2)$ and y_2 is the value of $Y_{\theta}(t)$ for the remaining period of 644 645 concern (with Delta as the dominant circulating viral strain).

$$Y_{\theta}(t) = \begin{cases} y_0 & \theta_0 \le t < \theta_1 \\ y_1 & \theta_1 \le t < \theta_2 \\ \vdots & \vdots \\ y_m & \theta_m \le t < \infty \end{cases}$$
(38)

646 where *m* is the number of viral variants that have emerged up to the current time, $\theta_0 \equiv t_0$, and 647 $y_0 \equiv 1$. Here, we consider m = 2.

648 Equations of the Auxiliary Measurement Model

649 As in the study of Lin et al. [2], we assumed that only symptomatic persons are detected 650 in testing. The accumulation of symptomatic persons is governed by

$$\frac{dC_S}{dt} = (1 - f_A) \left[k_L \left(E_{5,M} + E_{5,P} + E_{5,Q} \right) + \left(\frac{k_L}{5} \right) E_V \right]$$
(39)

where $C_S(t)$ is the cumulative number of symptomatic persons (cases) at time *t*. Here, unlike in the study of Lin et al. [2], the expression for $C_S(t)$ accounts for exposed persons in quarantine.

Initially, $C_S = 0$. We numerically integrated Appendix Equation (39) together with the ODEs of the compartmental model. From the trajectory for C_S , we derive a prediction for the expected number of new COVID-19 cases reported on calendar date \mathcal{D}_i , $I(t_i, t_{i+1})$, using the following equation:

$$I(t_i, t_{i+1}) = f_D[C_S(t_{i+1}) - C_S(t_i)]$$
(40)

where f_D is an adjustable region-specific parameter characterizing the time-averaged fraction of symptomatic cases detected and reported, t_i corresponds to midnight on the *i*th day after January 21, 2020, and $t_{i+1} - t_i$ is the reporting interval (1 d). We compare $I(t_i, t_{i+1})$ to δC_i , the number of new cases reported on calendar date \mathcal{D}_i .

661 Definition of the Likelihood Function

Bayesian inference relies on the definition of a likelihood, which here serves the purpose 662 663 of assessing the compatibility of available surveillance data with adjustable (free) parameter values. Let us use $\{\delta C_i\}_{i=0}^d$ to denote the daily case reporting data available between 0 and d 664 days after midnight on January 21, 2020 (the date of the first case report in the US) and let 665 $D = \{\delta C_i\}_{i=0}^d$. Let us use $\theta_F(n, m)$ to denote the set of adjustable (free) parameter values. The 666 number of adjustable parameters, $|\theta_F|$, depends on *n*, the number of social-distancing periods 667 considered beyond an initial social-distancing period, and m, the number of SARS-CoV-2 668 variants under consideration. As in the study of Lin et al. [2], we assume that δC_i , the number of 669 new COVID-19 cases detected over a 1-d period and reported on calendar date \mathcal{D}_i for a given 670 671 region, is a random variable and its expected value follows a model-derived deterministic trajectory given by $I(t_i, t_{i+1})$ (Equation 40). We assume that day-to-day fluctuations in the 672 random variable are independent and characterized by a negative binomial distribution $NB(r, q_i)$, 673

674 which has two parameters, r > 0 and $q_i \in (0,1)$. Note that $\mathbb{E}[NB(r, q_i)] = r(1 - q_i)/q_i$. We

assume that this distribution has the same dispersion parameter r across all case reports. With

these assumptions, we arrive at the following likelihood function:

$$\mathcal{L}(\theta_F(n,m); \{\delta C_i\}_{i=0}^d) = \prod_{i=0}^d \mathcal{L}_i(\theta_F(n,m); \delta C_i)$$
(41)

677 where

$$\mathcal{L}_{i}(\theta_{F}(n,m);\delta C_{i}) = \operatorname{nbinom}(\delta C_{i};r,q_{i}) = \binom{\delta C_{i}+r-1}{\delta C_{i}-1}q_{i}^{r}(1-q_{i})^{\delta C_{i}}$$
(42)

678 and

$$q_i = \frac{r}{r + I(t_i, t_{i+1})}.$$
(43)

In these equations, *i* is an integer indicating the date \mathcal{D}_i and period (t_i, t_{i+1}) ; nbinom $(\delta C_i; r, q_i)$ is the probability mass function of the negative binomial distribution NB (r, q_i) , and $\theta_F(n, m) =$ $\{t_0, \beta, \sigma, \tau_1, \dots, \tau_n, p_0, p_1, \dots, p_n, \lambda_0, \lambda_1, \dots, \lambda_n, \theta_1, \dots, \theta_m, y_1, \dots, y_m, f_D, r\}$ for $n \ge 1$ and $m \ge 1$; $\theta_F(0,0) = \{t_0, \beta, p_0, \lambda_0, f_D, r\}$.

683 **Parameters**

Each model parameter is briefly described in Tables 1–3. These parameters have either fixed values or adjustable values (i.e., values inferred from surveillance data). The fixed values may be universal (i.e., applicable to all MSAs of interest) or MSA-specific. All inferred parameter values are MSA-specific. In addition, the measurement model (Appendix Equations 39 and 40) has one adjustable MSA-specific parameter, f_D , and the likelihood function

(Appendix Equations 41–43) has one adjustable MSA-specific parameter, r. Values of the other likelihood parameters, $q_0, ..., q_d$, are constrained and are determined using Appendix Equation 43.

The model shares 19 + 3n parameters with the model of Lin et al. [2], including 692 parameters that define the initial condition $(t_0, I_0, \text{ and } S_0)$. (Recall that n is the number of social-693 694 distancing periods being considered beyond the initial social-distancing period.) The shared 695 parameters are $t_0, I_0, S_0, \beta, \sigma, \tau_1, \dots, \tau_n, p_0, \dots, p_n, \lambda_0, \dots, \lambda_n, \rho_A, \rho_E, m_b, f_A, f_H, f_R, k_L, k_Q, j_Q, \eta_B$ c_A , c_H , and c_I . As in the study of Lin et al. [2], we inferred MSA-specific values for the 696 following parameters: $t_0, \beta, \sigma, p_0, \dots, p_n$, and $\lambda_0, \dots, \lambda_n$. We also inferred MSA-specific values 697 for $\tau_1, ..., \tau_n$ provided that $n \ge 1$. As in the study of Lin et al. [2], the remaining 14 parameters 698 shared between the old and new models $(I_0, S_0, \rho_A, \rho_E, m_b, f_A, f_H, f_R, k_L, k_Q, j_Q, c_A, c_H, \text{ and } c_I)$ 699 were taken to have fixed values, and we adopted the settings of Lin et al. [2] for these parameters 700 701 (Table 3). These settings are universal except for the setting for S_0 , the total population, which is MSA-specific. 702

Our extension of the model of Lin et al. [2] introduces 5 + 2(m + 1) + (d + 1)

parameters, where m (= 0, 1 or 2) is the number of SARS-CoV-2 variants being considered and

705 *d* is the number of days since January 21, 2020: $\theta_0, \dots, \theta_m, y_0, \dots, y_m, m_h, f_0, f_1, f_2, k_V$, and

706 μ_0, \dots, μ_d . The θ and y parameters are variant takeover times and transmissibility factors,

respectively, except that the value of θ_0 is defined as t_0 and the value of y_0 is defined as 1. The

Alpha transmissibility factor y_1 , the Alpha takeoff time θ_1 , the Delta transmissibility factor y_2 ,

and the Delta takeoff time θ_2 were inferred for each MSA with m = 2 (cf. Table 1). The

transmissibility factors were each constrained to be greater than or equal to 1. The settings for

 μ_0, \dots, μ_d are empirical and MSA-specific. Each μ_i is set such that $\mu_i S_0 \times 1$ d is the number of 711 vaccinations completed over the past 1-d period nearest to the *i*th day after January 21, 2020. As 712 noted earlier, the number of completed vaccinations was obtained for each MSA from Covid Act 713 Now using the Covid Act Now Data API [1]. In the spreadsheet accessed daily, the 714 'metrics.vaccinationsCompletedRatio' column gives the percentage of the total population that 715 has received the recommended number of doses: one dose for Ad26.CoV2.S (Janssen, Johnson 716 & Johnson) or two doses for mRNA-1273 (Moderna) and BNT162b2 (Pfizer-BioNTech). As a 717 718 simplification, we considered all completed vaccinations to be equivalent. The parameters m_h , f_0, f_1, f_2 , and k_V were assigned fixed universal estimates (Table 3). Each of these estimates is 719 explained below. 720

The rate constant k_{v} characterizes the rate of transition out of compartment V_{i} for i =721 1, ..., n_V . Recall that, in the model, susceptible persons enter V_1 upon vaccination (Figure 1, 722 Appendix Figure 1). The values of n_V (= 6) and k_V (= 0.3 d⁻¹) were selected so that the time a 723 person spends in V_1, \ldots, V_{n_V} , which we will denote as t_V , is distributed approximately the same as 724 \tilde{t}_{V} , the waiting time between vaccination of a previously uninfected person and detection of 725 726 vaccine-induced SARS-CoV-2-specific IgG antibodies [3] (Appendix Figure 2). According to the model, the time that a person spends in V_1, \ldots, V_{n_V} is distributed according to the probability 727 density function $f(t_V; n_V, k_V) = k_V^{n_V} t_V^{n_V-1} e^{-k_V t_V} / (n_V - 1)!$, i.e., t_V is Erlang distributed with 728 shape parameter $n_V = 6$ and rate parameter $k_V = 0.3 \text{ d}^{-1}$. As can be seen in Appendix Figure 2, 729 730 the cumulative distribution function of this Erlang distribution reasonably captures the empirical cumulative distribution of waiting times observed in the longitudinal study of Korodi et al. [3]. 731 Thus, in the model, passage through $V_1, ..., V_6$ with rate constant $k_V = 0.3 \, d^{-1}$ accounts for the 732

variable and significantly non-zero amount of time required for development of a protectiveantibody response after vaccination.

The parameters $f_0 > f_1$, $f_1 > f_2$, and f_2 are fractions that characterize the average 735 effectiveness of vaccines used in the US and that determine the sizes of (mutually exclusive) 736 subpopulations of vaccinated persons having different susceptibilities to productive infection 737 (i.e., an infection that can be transmitted to others): $S_{V,1}$, $S_{V,2}$, $S_{V,3}$, and $S_{V,4}$ (Figure 1, Appendix 738 Figure 1). We assume that persons in the $S_{V,1}$ subpopulation are susceptible to productive 739 infection by any of the viral strains considered, and in contrast, we assume that persons in the 740 $S_{V,4}$ subpopulation are susceptible to productive infection by none of the viral strains considered. 741 Persons in the $S_{V,2}$ subpopulation are taken to be susceptible to productive infection by the Alpha 742 and Delta variants but not viral strains in circulation before the emergence of Alpha. Persons in 743 the $S_{V,3}$ subpopulation are taken to be susceptible to productive infection by the Delta variant but 744 not the Alpha variant or viral strains in circulation before the emergence of Alpha. The quantity 745 $1 - f_0$ defines the fraction of vaccinated persons who enter the $S_{V,1}$ subpopulation after exiting 746 V_6 , the quantity $f_0 - f_1$ defines the fraction of vaccinated persons who enter the $S_{V,2}$ 747 subpopulation after exiting V_6 , the quantity $f_1 - f_2$ defines the fraction of vaccinated persons 748 who enter the $S_{V,3}$ subpopulation after exiting V_6 , and f_2 defines the fraction of vaccinated 749 persons who enter the $S_{V,4}$ subpopulation after exiting V_6 . We take f_0 to characterize vaccine 750 751 effectiveness before the emergence of Alpha. According to Thompson et al. [4], vaccine effectiveness was initially 90%. Thus, we set $f_0 = 0.9$. We take f_1 to characterize vaccine 752 753 effectiveness after the emergence of Alpha but before the emergence of Delta. According to Puranik et al. [5], in May 2021, vaccine effectiveness was 81%. Thus, we set $f_1 = 0.81$. We take 754 f_2 to characterize vaccine effectiveness after the emergence of Delta. According to Tang et al. 755

[6], the effectiveness of two doses of the Pfizer-BioNTech vaccine (BNT162b2) against Delta is 53.5% and the effectiveness of two doses of the Moderna vaccine (mRNA-1273) against Delta is 84.8%. Taking the average of these figures, we set $f_2 = 0.69$.

The parameter m_h characterizes the reduced risk of severe disease for a vaccinated

person in the case of a breakthrough infection. We set $m_h = 0.04$, i.e., we assumed that there is a

761 25-fold reduction in the risk of severe disease for infected persons who have been vaccinated,

which is consistent with the observations of Lopez Bernal et al. [7].

763 Notable New Modeling Assumptions

It should be noted that we treat the incubation period for newly infected (exposed) 764 vaccinated persons differently than for newly infected (exposed) unvaccinated persons (Figure 1, 765 Appendix Figure 1). For unvaccinated persons, as in the study of Lin et al. [2], we divide 766 exposed persons in the incubation period of infection into five subpopulations: $E_{1,M}$, ..., $E_{5,M}$ for 767 exposed persons who are mixing (i.e., persons who are not practicing social distancing), 768 $E_{1,P}, \dots, E_{5,P}$ for exposed persons who are practicing social distancing, and $E_{1,Q}, \dots, E_{5,Q}$ for 769 770 exposed quarantined persons. Persons move through the five stages of the incubation period sequentially. In contrast, as a simplification, for vaccinated persons, we consider only a single 771 exposed population: E_V . We take persons to exit E_V with rate constant $k_L/5$ (Appendix Figure 772 1). With this choice, the duration of the incubation period of infection is the same, on average, 773 for both vaccinated and unvaccinated persons. The average duration is $5/k_L$ (about 5 d) in both 774 cases. The difference is that the duration of the incubation period is Erlang distributed for 775 776 unvaccinated persons, as discussed by Lin et al. [2], but exponentially distributed for vaccinated 777 persons.

- As indicated in Equation (29), we take vaccinated persons with productive infections to be equally as infectious as unvaccinated persons.
- As noted earlier, we take all vaccinated persons to be mixing (i.e., to not be practicing social distancing). Thus, populations of infected vaccinated persons $(E_V, I_V, \text{ and } A_V)$ contribute to $\phi_M(t)$ (Appendix Equation 29) but not $\phi_P(t)$ (Appendix Equation 30).
- As indicated in Appendix Equation 31, we consider pre-symptomatic exposed and asymptomatic unvaccinated persons to be eligible for vaccination and, thus, these persons contribute to the consumption of vaccine doses (i.e., these persons account for a portion of the number of completed vaccinations on a given day i, $\mu_i S_0 \times 1$ d). However, we do not move these persons to vaccinated compartments. The reason is that exposed and asymptomatic persons are expected to develop immunity faster through recovery from infection (i.e., movement to R_U) than from vaccination.
- As indicated in Appendix Equation 31, we do not consider symptomatic, quarantined,
 severely ill and hospitalized/isolated-at-home, and deceased persons to be eligible for
 vaccination.

793 Inference Approach

Recall that θ_F denotes the set of all adjustable parameters. As in the study of Lin et al. [2], for each MSA, we inferred MSA-specific adjustable parameter values θ_F using all MSAspecific surveillance data available up to a specified day of inference \mathcal{D}_d (i.e., the *d*th day after January 21, 2020). We took a Bayesian inference approach, meaning that, for a given dataset, we generated parameter posterior samples (a collection of θ_F 's) through Markov chain Monte Carlo (MCMC) sampling. The parameter posterior samples provide a probabilistic characterization of

the adjustable parameter values consistent with the dataset used in inference. By drawing 800 samples from the parametric posterior distribution, we generated a posterior predictive 801 802 distribution for $I(t_i, t_{i+1})$ for each *i* of interest. We considered all days from January 21, 2020 to October 31, 2021. In other words, for each *i* of interest, a prediction for $I(t_i, t_{i+1})$ was generated 803 804 for each of many θ_F 's drawn randomly (with uniform probability) from the parametric posterior distribution. The resulting distribution of $I(t_i, t_{i+1})$ values is the posterior predictive distribution 805 for $I(t_i, t_{i+1})$. Recall that $I(t_i, t_{i+1})$ is given by Appendix Equation 40 and corresponds to 806 $\mathbb{E}[\delta C_i]$, the expected number of new COVID-19 cases detected over a 1-d surveillance interval 807 808 and reported for the *i*th day after January 21, 2020. Observation noise was injected into the posterior predictive distributions by replacing each sampled value for $I(t_i, t_{i+1})$ with 809 $X_i \sim \text{NB}(r, q_i)$, where r is a member of the sampled set of parameter values θ_F used to generate 810 the prediction of $I(t_i, t_{i+1})$ and q_i is given by Equation 43. 811

According to Bayes' theorem, given surveillance data $D = \{\delta C_i\}_{i=0}^d$, the parametric posterior is given as

$$\mathbb{P}\{\theta_F|D\} = \frac{\mathbb{P}\{D|\theta_F\} \mathbb{P}\{\theta_F\}}{Z}$$
(44)

814 where $\mathbb{P}\{\theta_F\}$ is the prior (which is formulated to capture knowledge of θ_F external to *D* or to 815 express lack of such knowledge), $\mathbb{P}\{D|\theta_F\}$ is the likelihood defined by Appendix Equations 41– 816 43, and *Z* is a normalizing constant. We assumed a proper uniform prior, i.e., for each adjustable 817 parameter, we assumed that all values between specified lower and upper bounds are equally 818 likely before consideration of *D*. We used the same bounds as in the study of Lin et al. [2]. Then 819 we used an adaptive MCMC (aMCMC) algorithm [8] to generate samples from $\mathbb{P}\{D|\theta_F\} \mathbb{P}\{\theta_F\}$,

820 which is proportional to $\mathbb{P}\{\theta_F | D\}$. Thus, the relative probabilities of parameter sets θ_F according 821 to $\mathbb{P}\{\theta_F | D\}$ are correctly represented by the samples.

822	Specifically, the adaptive MCMC algorithm [8] generates samples from the multivariate
823	parametric posterior for adjustable model parameters (t_0 , β , and parameters for variant
824	emergence and social distancing), the measurement model parameter f_D , and the likelihood
825	parameter r (Tables 1 and 2). This algorithm is available within the PyBioNetFit software
826	package [9]. Use of the algorithm was performed as described by Lin et al. [2]. The report of
827	Neumann et al. [9] includes helpful general usage advice, which was followed in this study.
828	Inference jobs were executed on a computer cluster.
829	Each inference was conditioned on the compartmental model of Figure 1 (Appendix
830	Equations 1–38), settings for the structural parameters m (the number of SARS-CoV-2 variants
831	under consideration) and n (the number of social-distancing periods under consideration beyond
832	an initial social-distancing period), the measurement model (Appendix Equations 39 and 40), and
833	fixed parameter estimates (Tables 1 and 2), including empirical daily per-capita vaccination
834	rates (i.e., the settings for μ_i in Appendix Equation 37). We assumed a proper uniform prior for
835	each adjustable parameter [2] and a negative binomial likelihood function (Appendix Equations
836	41–43). Use of proper uniform priors means that MAP estimates are maximum likelihood

estimates (MLEs). In each inference, the data entering the likelihood function, $D = \{\delta C_i\}_{i=0}^d$

838 (Appendix Equation 41), were MSA-specific daily reports of newly detected COVID-19 cases

available up to the date of inference D_d (i.e., the *d*-th day after January 21, 2020). Thus, all

840 inferences are region-specific and time-dependent.

841 Use of Model Selection to Determine Intervals of Step Functions

Variant takeover times, $\theta = (\theta_1, \theta_2)$, and start times of social-distancing periods, $\tau =$ 842 $(\sigma, \tau_1, ..., \tau_n)$, were inferred from data; however, changes of the associated time-dependent step 843 functions, $Y_{\theta}(t)$, $P_{\tau}(t)$, and $\Lambda_{\tau}(t)$, were introduced only when an increase in model complexity 844 was deemed to be justified. Each decision to introduce variant takeover or start of a new social-845 846 distancing period (beyond the initial period) was made using a model-selection procedure, which is described below. It should be noted that y_1 and y_2 are parameters of $Y_{\theta}(t)$, p_0 , p_1 , ..., p_n are 847 parameters of $P_{\tau}(t)$, and $\lambda_0, \lambda_1, \dots, \lambda_n$ are parameters of $\Lambda_{\tau}(t)$. These parameters determine the 848 values of the step functions over different periods. For example, for $n \ge 1$, p_1 is the value of 849 $P_{\tau}(t)$ and λ_1 is the value of $\Lambda_{\tau}(t)$ for the period $t \in [\tau_1, \tau_2)$. Similarly, y_1 is the value of $Y_{\theta}(t)$ 850 for the period $t \in [\theta_1, \theta_2)$, and y_2 is the value of $Y_{\theta}(t)$ for the period $t \in [\theta_2, t_{\text{final}})$, where t_{final} 851 852 corresponds to the date of inference (October 31, 2021).

We started with a setting of n = 7 for each MSA of interest (i.e., 8 total social-distancing 853 stages). To determine if n could be reduced, we conducted so-called "parsimony checks". In a 854 855 parsimony check, 100 MLE curves, each constituting a fit to the data, were generated via 856 optimization jobs (started at 100 randomly selected locations in parameter space). The total number of social-distancing stages n + 1 in the model was 1 less than for the current proposed 857 best fit. Each of the 100 fits was then visually inspected to check whether or not the following 858 criteria held: 1) the quality of fit is acceptable (i.e., comparable to what is obtained with the 859 current proposed best fit); 2) Alpha and Delta surges (identified by sequencing data) are 860 explained at least partly by increased transmissibility; 3) social-distancing setpoint parameter 861 values are feasible; 4) social-distancing changes proximal to an Alpha or Delta surge (if any) 862 863 occur only after an increase in transmissibility. If one or more of these conditions was not satisfied, we accepted the proposed best fit as the most parsimonious fit to the data. If all of the 864

conditions held, we had a new proposed best fit, and the parsimony check was repeated for a
model with one less social-distancing stage.

867 Simulations

- After specification of parameter values (Tables 1–3), we used the SciPy
- 869 (<u>https://www.scipy.org</u>) interface to LSODA [11] to numerically integrate the system of coupled
- ODEs consisting of the 40 ODEs of the compartmental model and the 1 ODE of the
- 871 measurement model (Appendix Equations 1–39). The initial condition was defined by settings
- for t_0 , I_0 , and S_0 (Tables 1–3). Integration combined with use of Appendix Equation 40 yielded a
- prediction of the expected number of new cases detected for each 1-d surveillance period of
- interest in the past or future: $I(t_i, t_{i+1})$, where t_i corresponds to midnight on the *i*th day after
- January 21, 2020. To account for randomness in case detection and reporting, we replaced

876 $I(t_i, t_{i+1})$ with $X_i \sim NB(r, q_i)$, where q_i is given by Appendix Equation 43.

877 Appendix References

- [1] Covid Act Now. US COVID risk and vaccine tracker. 2021 [cited 2021 Sep 29]
 https://covidactnow.org/
- [2] Lin YT, Neumann J, Miller EF, Posner RG, Mallela A, Safta C, Ray J, Thakur G,
- 881 Chinthavali S, Hlavacek WS. Daily forecasting of regional epidemics of Coronavirus
- 882 Disease with Bayesian uncertainty quantification, United States. Emerg Inf Dis.
- 883 2021;27:767–78. <u>https://doi.org/10.3201/eid2703.203364</u>
- 884 [3] Korodi M, Rákosi K, Jenei Z, Hudák G, Horváth I, Kákes M, et al. Longitudinal
- 885 determination of mRNA-vaccination induced strongly binding SARS-CoV-2 IgG
- antibodies in a cohort of healthcare workers with and without prior exposure to the novel

- coronavirus. Vaccine. 2022;40:37: 5445–5451.
- 888 https://doi.org/10.1016/j.vaccine.2022.07.040
- [4] Thompson MG, Burgess JL, Naleway AL, Tyner HL, Yoon SK, Meece J, et al. Interim
- estimates of vaccine effectiveness of BNT162b2 and mRNA-1273 COVID-19 vaccines
- in preventing SARS-CoV-2 infection among health care personnel, first responders, and
- other essential and frontline workers—eight U.S. locations, December 2020–March 2021.
- 893 MMWR Morb Mortal Wkly Rep. 2021;70:495–500.
- 894 <u>http://dx.doi.org/10.15585/mmwr.mm7013e3</u>
- [5] Puranik A, Lenehan PJ, Silvert E, Niesen MJM, Corchado-Garcia J, O'Horo JC, et al.
- 896 Comparison of two highly-effective mRNA vaccines for COVID-19 during periods of
- Alpha and Delta variant prevalence. [cited 2021 Oct 8]
- 898 <u>https://www.medrxiv.org/content/10.1101/2021.08.06.21261707v3</u>
- [6] Tang P, Hasan MR, Chemaitelly H, Yassine HM, Benslimane FM, Al Khatib HA, et al.
- 900 BNT162b2 and mRNA-1273 COVID-19 vaccine effectiveness against the SARS-CoV-2
- 901 Delta variant in Qatar. Nat Med. 2021;27:2136–43.
- 902 <u>https://www.nature.com/articles/s41591-021-01583-4</u>
- 903 [7] Lopez Bernal J, Andrews N, Gower C, Gallagher E, Simmons R, Thelwall S, et al.
- Effectiveness of Covid-19 Vaccines against the B.1.617.2 (Delta) variant. N Engl J Med.
- 905 2021;385:585–94. <u>https://doi.org/10.1056/NEJMoa2108891</u>
- 906 [8] Andrieu C, Thoms J. A tutorial on adaptive MCMC. Stat Comput. 2008;18:343–73.
- 907 https://doi.org/10.1007/s11222-008-9110-y
- 908 [9] Neumann J, Lin YT, Mallela A, Miller EF, Colvin J, Duprat AT, Chen Y, Hlavacek WS,
- 909 Posner RG. Implementation of a practical Markov chain Monte Carlo sampling algorithm

- 910 in PyBioNetFit. Bioinformatics. 2022;38:1770–2.
- 911 https://doi.org/10.1093/bioinformatics/btac004
- 912 [10] Burnham KP, Anderson DR. Multimodal inference: understanding AIC and BIC
- 913 in model selection. Sociol Methods Res. 2016;33:261–304.
- 914 <u>https://doi.org/10.1177/0049124104268644</u>
- 915 [11] Hindmarsh AC. ODEPACK, a systematized collection of ODE solvers. In
- 916 Stepleman RS, editor. Scientific computing: applications of mathematics and computing
- to the physical sciences. Amsterdam: North-Holland Publishing Company; 1983. p. 55–
- 918 64.

920

State variable Description (population) S_M Population of susceptible unvaccinated persons who are mixing (i.e., not practicing social distancing) Population of susceptible unvaccinated persons who are practicing social S_P distancing $S_{V,1}$ Population of vaccinated unexposed persons who developed an immune response to vaccination that does not protect against productive infection by ancestral strains or the Alpha and Delta variants $S_{V,2}$ Population of vaccinated unexposed persons who developed an immune response to vaccination that protects against productive infection by ancestral strains but not the Alpha or Delta variants $S_{V,3}$ Population of vaccinated unexposed persons who developed an immune response to vaccination that protects against productive infection by ancestral strains and the Alpha variant but not the Delta variant Population of vaccinated unexposed persons who developed an immune $S_{V.4}$ response to vaccination that protects against productive infection by ancestral strains and the Alpha and Delta variants $V_i \ (i = 1, ..., 6)$ Population of vaccinated persons in the *i*th stage of immune response to vaccination $E_{i,M}$ (*i* = 1, ...,5) Population of exposed unvaccinated persons in the *i*th stage of the incubation period of infection and who are mixing E_{iP} (*i* = 1, ...,5) Population of exposed unvaccinated persons in the *i*th stage of the incubation period of infection and who are practicing social distancing $E_{i,0}$ (*i* = 2, ...,5) Population of exposed unvaccinated persons in the *i*th stage of the incubation period of infection and who are quarantined E_V Population of vaccinated persons in the incubation period of a productive

infection (i.e., an infection that can be transmitted to others)

Appendix Table 1. State variables of the compartmental model

A_M	Population of asymptomatic unvaccinated persons who are in the immune clearance phase of infection and who are mixing
A_P	Population of asymptomatic unvaccinated persons who are in the immune clearance phase of infection and who are practicing social distancing
A_Q	Population of asymptomatic unvaccinated persons who are in the immune clearance phase of infection and who are quarantined
A_V	Population of asymptomatic vaccinated persons who are in the immune clearance phase of a productive infection (i.e., an infection that can be transmitted to others)
I _M	Population of infectious, symptomatic, and unvaccinated persons with mild disease who are mixing
I_P	Population of infectious, symptomatic, non-vaccinated, and infectious persons with mild disease who are practicing social distancing
I_Q	Population of infectious, symptomatic, and unvaccinated persons with mild disease who are quarantined
I_V	Population of infectious, symptomatic, and vaccinated persons with mild disease
R_U	Population of recovered unvaccinated persons
R_V	Population of recovered vaccinated persons
H_U	Population of unvaccinated persons with severe disease who are hospitalized or isolated at home
H_V	Population of vaccinated persons with severe disease who are hospitalized or isolated at home
D	Population of deceased persons





Appendix Figure 1. Expanded illustration of the new compartmental model. In the extended 923 924 model, vaccination was considered by allowing susceptible and recovered persons to transition into a vaccinated compartment, either V_1 and R_V . Susceptible (recovered) persons who have 925 completed vaccination move into the $V_1(R_V)$ compartment. The susceptible persons who move 926 into V_1 are drawn from S_M (populated by susceptible persons who are mixing and unprotected by 927 social distancing) and from S_P (populated by susceptible persons who are protected by social 928 distancing). After susceptible persons enter V_1 , they can move through a series of additional 929 compartments (V_2 through V_6), which are included to capture the time needed for immunity to 930 develop after completion of vaccination. We estimate that the time needed to acquire immunity 931 932 after vaccination is approximately three weeks based on longitudinal studies of anti-spike protein IgG levels [3]. Persons who exit the V_6 compartment without becoming infected enter one of the 933 following compartments: $S_{V,1}$, $S_{V,2}$, $S_{V,3}$, or $S_{V,4}$. Persons in $S_{V,1}$ are taken to remain susceptible 934

to productive infection by all SARS-CoV-2 strains of interest (Alpha, Delta, and ancestral 935 strains). Persons in $S_{V,2}$ are taken to be susceptible to SARS-CoV-2 Alpha and Delta variants. 936 Persons in $S_{V,3}$ are taken to be susceptible to Delta. Persons in $S_{V,4}$ are taken to be protected 937 against all strains of interest. Infection of persons in $S_{V,3}$ is only allowed if Delta is present, i.e., 938 at times $t > \theta_2$. Infection of persons in $S_{V,2}$ is only allowed if Alpha or Delta is present, i.e., at 939 times $t > \theta_1$. Vaccinated persons in compartments V_1 through V_6 and compartment $S_{V,1}$ are 940 allowed to become infected at any time, at which point they transition to compartment E_{ν} , 941 942 consisting of vaccinated persons who were exposed before development of vaccine-induced immunity. Persons in compartment $S_{V,2}$ are allowed to become infected if $t \ge \theta_1$. Similarly, 943 persons in compartment $S_{V,3}$ are allowed to become infected if $t \ge \theta_2$. Possible outcomes for 944 persons in E_V are taken to be the same as those for unvaccinated exposed persons; however, the 945 incubation period is taken to be distinct. Persons in E_V can experience asymptomatic disease 946 947 (upon entering A_V) or they can become symptomatic (upon entering I_V). Persons in A_V eventually recover, entering compartment R_V . Persons in I_V can progress to severe disease (upon 948 entering H_V) or recover (upon entering R_V). Persons in H_V either recover (moving into R_V) or die 949 (moving into D). Persons who have recovered from infection, in the R_{II} compartment, move 950 directly into the R_V compartment upon vaccination. Persons in the R_U and R_V compartments are 951 taken to have full immunity. The vaccination rate at which susceptible and recovered persons 952 move into vaccinated compartments is updated daily for consistency with the empirical overall 953 954 rate of vaccination, which we extract daily from the COVID Act Now Data API [1]. The relative values of the vaccination rate are set such that each person eligible for vaccination has the same 955 probability of being vaccinated. All unvaccinated persons are taken to be eligible for vaccination 956 except symptomatic persons (in compartments I_M and I_P), persons who are hospitalized or 957

severely ill at home (in compartment H), quarantined persons (in the various compartments 958 labeled with a Q subscript), and deceased persons (in compartment D). It should be noted that 959 asymptomatic, non-quarantined persons (in compartments A_M and A_P) and presymptomatic, non-960 961 quarantined persons (in the *E* compartments) are taken to be eligible (and to influence the 962 vaccination rate constants) but, as a simplification, these persons are not explicitly tracked as 963 vaccinated or unvaccinated because each of these persons will eventually enter either the D 964 compartment or the R_{II} compartment, at which point they will have immunity. In the model, the effects of SARS-CoV-2 variants are captured by a time-dependent dimensionless multiplier 965 $Y_{\theta}(t)$ of the rate constant β . This rate constant, which appears in Appendix Equations 1-4, 18-966 22, and 24, determines the rate of disease transmission within the subpopulation unprotected by 967 social-distancing behaviors when $Y_{\theta}(t) = 1$. We take $Y_{\theta}(t) = 1$ for times $t < \theta_1$, i.e., for the 968 initial period of the COVID-19 pandemic in the US that we take to have started on January 21, 969 2020. We take $Y_{\theta}(t)$ to have the form of a step function with distinct values greater than 1 for 970 periods starting at $t = \theta_1$ and $\theta_{k+1} > \theta_k$ for k = 1, ..., m. Thus, the model allows for m distinct 971 periods of variant strain dominance delimited by a set of start times $\theta = \{\theta_1, \dots, \theta_m\}$. We 972 considered m = 2. We assume that variants differ only in transmissibility. 973



975 Appendix Figure 2. Comparison of an Erlang cumulative distribution function with shape 976 parameter $n_V = 6$ and rate parameter $k_V = 0.3 d^{-1}$ and the empirical cumulative distribution of 977 waiting times (\tilde{t}_V values) observed in the longitudinal study of Korodi et al. [3]. The waiting 978 time \tilde{t}_V is the time between vaccination of a previously uninfected person and detection of 979 vaccine-induced SARS-CoV-2-specific IgG antibodies.